{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:40:36Z","timestamp":1786650036636,"version":"build-2736575974"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2016,4]]},"abstract":"<jats:p>Lung cancer is the leading cause of cancer deaths worldwide, and around 75% to 80% of lung cancers are detected in advanced stage. Multiple genetic mutations are identified and reported in adenocarcinoma of the lung. Various pulmonary samples can be tested for molecular mutations in lung cancer. However, feasibility of molecular profiling of pleuroscopic pleural biopsies in lung adenocarcinoma is not reported. We describe a case of advanced adenocarcinoma of lung with positive anaplastic lymphoma tyrosine kinase mutation on pleuroscopic pleural biopsy and improved with oral crizotinib. The current case highlights the feasibility of pleuroscopy.-guided pleural biopsies in molecular profiling of lung adenocarcinoma.<\/jats:p>","DOI":"10.4103\/0973-1482.154053","type":"journal-article","created":{"date-parts":[[2016,7,26]],"date-time":"2016-07-26T05:22:30Z","timestamp":1469510550000},"page":"1090-1092","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["ALK positivity on pleuroscopic pleural biopsy in lung adenocarcinoma"],"prefix":"10.4103","volume":"12","author":[{"given":"Preyas J.","family":"Vaidya","sequence":"first","affiliation":[{"name":"Institute of Pulmonology, Medical Research and Development, Mumbai, Maharashtra, India"},{"name":"Lung Care Team, Fortis Hospitals, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arvind H.","family":"Kate","sequence":"additional","affiliation":[{"name":"Institute of Pulmonology, Medical Research and Development, Mumbai, Maharashtra, India"},{"name":"Lung Care Team, Fortis Hospitals, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deval","family":"Mehta","sequence":"additional","affiliation":[{"name":"Institute of Pulmonology, Medical Research and Development, Mumbai, Maharashtra, India"},{"name":"Lung Care Team, Fortis Hospitals, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boman N.","family":"Dhabar","sequence":"additional","affiliation":[{"name":"Department of Oncology, Fortis Hospital, Mulund, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashant N.","family":"Chhajed","sequence":"additional","affiliation":[{"name":"Institute of Pulmonology, Medical Research and Development, Mumbai, Maharashtra, India"},{"name":"Lung Care Team, Fortis Hospitals, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2016,7,25]]},"reference":[{"key":"R1-20260109","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer Incidence and Mortality Worldwide. Sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int J Cancer"},{"key":"R2-20260109","doi-asserted-by":"crossref","first-page":"645","DOI":"10.6004\/jnccn.2013.0084","article-title":"Non-small cell lung cancer, version 2.2013","volume":"11","author":"Ettinger","year":"2013","journal-title":"J Natl Compr Cancer Netw"},{"key":"R3-20260109","first-page":"483","article-title":"Clinical and pathological profile of 73 patients with lung carcinoma: Is the picture changing?","volume":"5","author":"Chhajed","year":"1999","journal-title":"J Assoc Physicians India"},{"key":"R4-20260109","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.lungcan.2014.01.013","article-title":"Success and failure rates of tumor genotyping techniques in routine pathological samples with non-small-cell lung cancer","volume":"1","author":"Vanderlaan","year":"2014","journal-title":"Lung Cancer"},{"key":"R5-20260109","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1097\/JTO.0000000000000203","article-title":"Multiplexed molecular profiling of lung cancer using pleural effusion","volume":"7","author":"Akamatsu","year":"2014","journal-title":"J Thorac Oncol"},{"key":"R6-20260109","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1183\/09031936.95.08030407","article-title":"CYFRA 21-1 as a tumour marker for bronchogenic carcinoma","volume":"3","author":"Rapellino","year":"1995","journal-title":"Eur Respir J"},{"key":"R7-20260109","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1093\/annonc\/mdt295","article-title":"Diagnostic value of a novel fully automated immunochemistry assay for detection of ALK rearrangement in primary lung adenocarcinoma","volume":"10","author":"Ying","year":"2013","journal-title":"Ann Oncol"},{"key":"R8-20260109","doi-asserted-by":"crossref","first-page":"49","DOI":"10.4046\/trd.2014.77.2.49","article-title":"Molecular pathology of lung cancer: Current status and future directions","volume":"2","author":"Roh","year":"2014","journal-title":"Tuberc Respir Dis (Seoul)"},{"key":"R9-20260109","doi-asserted-by":"crossref","first-page":"204","DOI":"10.3389\/fonc.2014.00204","article-title":"Biomarkers that currently affect clinical practice in lung cancer: EGFR, ALK, MET, ROS-1, and KRAS","volume":"4","author":"Korpanty","year":"2014","journal-title":"Front Oncol."},{"key":"R10-20260109","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","volume":"10","author":"Mok","year":"2009","journal-title":"N Engl J Med"},{"key":"R11-20260109","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1056\/NEJMoa1006448","article-title":"Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer","volume":"18","author":"Kwak","year":"2010","journal-title":"N Engl J Med"},{"key":"R12-20260109","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nature05945","article-title":"Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer","volume":"7153","author":"Soda","year":"2007","journal-title":"Nature"},{"key":"R13-20260109","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s00432-014-1584-8","article-title":"Clinicopathologic characteristics of ALK rearrangements in primary lung adenocarcinoma with identified EGFR and KRAS status","volume":"3","author":"Wang","year":"2014","journal-title":"J Cancer Res Clin Oncol"},{"key":"R14-20260109","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1200\/JCO.2009.22.6993","article-title":"Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK","volume":"26","author":"Shaw","year":"2009","journal-title":"J Clin Oncol"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01363817-201612020-00117","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T19:01:18Z","timestamp":1786647678000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01363817-201612020-00117"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":14,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.4103\/0973-1482.154053","relation":{},"ISSN":["0973-1482","1998-4138"],"issn-type":[{"value":"0973-1482","type":"print"},{"value":"1998-4138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4]]}}}